BET inhibitors have shown efficacy across various types of cancer. They have been particularly effective in hematological malignancies, such as acute myeloid leukemia (AML) and multiple myeloma. Solid tumors, including breast cancer, prostate cancer, and non-small cell lung cancer, have also shown responsiveness to BETi. The effectiveness of BETi in these cancers is often linked to the dependency of these malignancies on BET-regulated oncogenes and super-enhancers.
